All In Biotech

Drug Trial Radar · NCT07613866

A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of HRS-3095 in Patients With Chronic Spontaneous Urticaria

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of HRS-3095 with Chronic Spontaneous in adults, and to explore the reasonable dosage of HRS-3095 for Chronic Spontaneous Urticaria.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • HRS-3095 TabletDrug

    HRS-3095 tablet.

  • HRS-3095 Tablet PlaceboDrug

    HRS-3095 tablet placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 4.Time frame: Up to 4 weeks.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.